AlphAIAlphAI — Financial news for AI agents
investing.comOCT 202 min read$MYGN

Why is Myriad Genetics stock surging today?

Myriad Genetics (MYGN) stock rose 21.4% in pre-market trading after announcing the sale of its Prenatal Health Testing Business to Labcorp for $210M in cash. The deal, expected to close by early 2027, includes four prenatal tests. CEO Sam Raha stated the transaction will boost revenue growth, profitability, and balance sheet strength, focusing on cancer care. The move follows a 16% year-over-year decline in prenatal revenue and a guidance cut.

Original reporting
investing.com
Published Oct 20, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The cash proceeds improve liquidity and allow Myriad to concentrate on its oncology portfolio, which analysts view more favorably.

02

Market read

The deal is a material corporate action that drove a double‑digit pre‑market rally, offering a clear trading catalyst.

03

What to watch

Potential regulatory hurdles for the divestiture and integration risk for Labcorp could delay cash receipt.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics has been under pressure from declining prenatal revenues and a full‑year guidance cut. The Labcorp transaction aims to monetize the underperforming unit.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a definitive agreement to sell its Prenatal Health Testing Business to Labcorp for $210 million, triggering a 21.4% pre‑open price surge.

Expected impact

likely upward pressure as investors price in the cash infusion and strategic focus on oncology

Evidence & confidence

Deal size is material for a mid‑cap, the stock already jumped 21% on the news, and analysts have upgraded the rating.

Market effects

Sector

Strengthens the genetics/diagnostics sector by highlighting divestiture trends and focus on oncology pipelines.

Regional

U.S. biotech market may see modest uplift as a high‑profile divestiture is confirmed.

Global

Limited to investors tracking M&A activity in the healthcare space.

Counterpoint

What could challenge this read

The sale could signal deeper weakness in Myriad's prenatal segment, suggesting the stock may be over‑reacting.

Key entities

  • company
    Myriad Genetics

    US‑listed genetics testing firm (ticker MYGN).

  • company
    Labcorp

    US‑listed clinical laboratory services provider (ticker LH).

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min